<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94223">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084355</url>
  </required_header>
  <id_info>
    <org_study_id>GNUH-2013-07-014</org_study_id>
    <nct_id>NCT02084355</nct_id>
  </id_info>
  <brief_title>Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain</brief_title>
  <official_title>Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although opioid rotation is well known treatment modality in reducing pain and
      opioid-induced neurotoxicity, it is not established whether opioid rotation is more
      appropriate or opioid escalation is more effective in controlling significant  pain in
      cancer patients under opioid medication.

      - The purpose of this study is to determine effective therapy out of opioid rotation and
      opioid dose escalation in patients with moderate to severe cancer pain who have been already
      treated with strong opioid.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scale</measure>
    <time_frame>Eighteen months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>opioid rotation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).
oral oxycodone : convert to oral hydromorphone or fentanyl patch
oral hydromorphone : convert to oral oxycodone or fentanyl patch
fentanyl patch : convert to oral oxycodone or oral hydromorphone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>opioid dose escalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.
oral oxycodone : maintain oral oxycodone and titrate the dose
oral hydromorphone : maintain oral hydromorphone and titrate the dose
fentanyl patch : maintain fentanyl patch and titrate the dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral oxycodone</intervention_name>
    <arm_group_label>opioid rotation</arm_group_label>
    <arm_group_label>opioid dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral hydromorphone</intervention_name>
    <arm_group_label>opioid rotation</arm_group_label>
    <arm_group_label>opioid dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl patch</intervention_name>
    <arm_group_label>opioid rotation</arm_group_label>
    <arm_group_label>opioid dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  patients who are being treated with one of strong opioids including oral oxycodone,
             oral hydromorphone, or fentanyl patch with range from 60 mg to 200 mg of oral
             morphine equivalent daily dose (MEDD)

          -  moderate to severe cancer pain (numeric rating scale more than 3) at screening

          -  patients without uncontrolled adverse effects associated with currently applied
             opioid

        Exclusion Criteria:

          -  previous opioid rotation

          -  unable to take oral medication

          -  life expectancy less than a month

          -  newly started chemotherapy and/or radiotherapy within past 2 weeks of screening

          -  serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase &gt;
             2.5 times of upper normal limit

          -  serum total bilirubin or creatinine &gt; 1.5 times of upper normal limit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Se-Il Go, M.D.</last_name>
    <phone>+82 55 750 9454</phone>
    <phone_ext>9454</phone_ext>
    <email>gose1@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se-Il Go, M.D.</last_name>
      <phone>+82 55 750 9454</phone>
      <phone_ext>9454</phone_ext>
      <email>gose1@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gyeongsang National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung Hun Kang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Significant cancer pain</keyword>
  <keyword>at least numeric rating scale 4</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
